| 13.2 0.38 (2.96%) | 05-01 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 16.58 |
1-year : | 19.37 |
| Resists | First : | 14.19 |
Second : | 16.58 |
| Pivot price | 12.91 |
|||
| Supports | First : | 12.7 |
Second : | 11.77 |
| MAs | MA(5) : | 12.71 |
MA(20) : | 12.92  |
| MA(100) : | 13.07 |
MA(250) : | 10.03 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 44.3 |
D(3) : | 35.6 |
| RSI | RSI(14): 52.1 |
|||
| 52-week | High : | 16.32 | Low : | 3.34 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ CTNM ] has closed below upper band by 32.9%. Bollinger Bands are 46.6% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 15 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 13.91 - 13.97 | 13.97 - 14.03 |
| Low: | 12.55 - 12.61 | 12.61 - 12.67 |
| Close: | 13.1 - 13.19 | 13.19 - 13.29 |
Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.
Fri, 01 May 2026
Contineum Therapeutics CSO Daniel Lorrain sells $54,694 in stock - Investing.com
Fri, 01 May 2026
Contineum (NASDAQ: CTNM) CSO trims stake under 10b5-1 plan - Stock Titan
Fri, 01 May 2026
Contineum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
Thu, 30 Apr 2026
Contineum Therapeutics (NASDAQ: CTNM) details 2026 virtual annual meeting - Stock Titan
Fri, 17 Apr 2026
Millennium Group (CTNM) reports shared 1,658,349-share stake via Schedule 13G - Stock Titan
Mon, 06 Apr 2026
Contineum Therapeutics CSO sells $56k in CTNM stock - Investing.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 33 (M) |
| Shares Float | 25 (M) |
| Held by Insiders | 1 (%) |
| Held by Institutions | 90.7 (%) |
| Shares Short | 2,780 (K) |
| Shares Short P.Month | 2,550 (K) |
| EPS | -2.18 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 6.98 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -17.4 % |
| Return on Equity (ttm) | -26.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.08 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -55 (M) |
| Levered Free Cash Flow | -37 (M) |
| PE Ratio | -6.09 |
| PEG Ratio | 0 |
| Price to Book value | 1.88 |
| Price to Sales | 0 |
| Price to Cash Flow | -7.8 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|